New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 26, 2013
18:58 EDTPIP, SIGASIGA says court reverses 'equitable payment stream' to PharmAthene
SIGA Technologies (SIGA) reported that the Delaware Supreme Court reversed the award of an "equitable payment stream" by the Court of Chancery in its May 31, 2012 Final Order and Judgment in PharmAthene (PIP) v. SIGA Technologies and also remanded the case to the Court of Chancery for further proceedings to determine appropriate damages. William J. Haynes II, SIGA's General Counsel, commented, "We are pleased with the Delaware Supreme Court ruling issued on Friday. The Supreme Court's decision states that PharmAthene may only obtain damages for its lost expectancy if it can prove them 'with reasonable certainty.' We intend to establish to the Chancery Court, consistent with that Court's earlier conclusions, that PharmAthene's evidence of expectancy damages is speculative and too uncertain, contingent, and conjectural to permit an award." Dr. Eric A. Rose, SIGA's Chief Executive Officer, commented, "While legal proceedings may continue, we will now focus with even greater intensity on growing and enhancing SIGA's business, executing our existing contract with BARDA, seeking approval and licensing of Arestvyrô from the U.S. Food and Drug Administration, and making greater use of our proven antiviral drug discovery and development capabilities."
News For SIGA;PIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:16 EDTPIPPharmAthene reports Valortim IDIQ contract fulfilled
PharmAthene announced that it has fulfilled its obligations under a fixed price, indefinite delivery, indefinite quantity, or IDIQ, contract, awarded in 2013 by the Biomedical Advanced Research and Development Authority for the company's anthrax anti-toxin, Valortim. Under the IDIQ contract, PharmAthene was selected to provide a specified quantity of its Valortim anthrax anti-toxin master cell bank for secure storage by the government as part of a risk mitigation strategy for anthrax medical countermeasures.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use